Antimicrobial resistance of Pseudomonas aeruginosa: surveillance report from Hunan Provincial Antimicrobial Resistance Surveillance System, 2012-2021
Author:
Affiliation:

1.Laboratory Center, Hunan Children's Hospital, Changsha 410007, China;2.Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha 410013, China;3.Center for Healthcare-associated Infection Control, Xiang-ya Hospital, Central South University, Changsha 410008, China;4.Hunan Provincial Antimicrobial Resistance Surveillance System Office, Changsha 410008, China;5.Department of Laboratory Medicine, Liuyang Traditional Chinese Medicine Hospital, Liuyang 410300, China;6.Department of Laboratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China;7.Department of Laboratory Medicine, Xiangtan Central Hospital, Xiangtan 411100, China;8.Medical Laboratory and Pathology Center, The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China;9.Department of Laboratory Medicine, Changsha Central Hospital, Changsha 410004, China;10.Department of Laboratory Medicine, The First Hospital of Changsha, Changsha 410005, China;11.Department of Laboratory Medicine, Zhangjiajie People's Hospital, Zhangjiajie 427000, China;12.Center of Laboratory Medicine, The First People's Hospital of Chenzhou, Chenzhou 423000, China;13.Hunan Provincial Healthcare-associated Infection Management Quality Control Center, Changsha 410008, China;14.National Clinical Research Center for Geriatric Disorders[Xiangya Hospital], Changsha 410008, China

Clc Number:

R378.21

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    Objective To understand the distribution and changes in antimicrobial resistance of clinically isolated Pseudomonas aeruginosa (P. aeruginosa) in the member hospitals of Hunan Provincial Antimicrobial Resistance Surveillance System from 2012 to 2021. Methods Antimicrobial susceptibility testing by disk diffusion or automated instrument was performed on clinical isolates. Testing results were determined according to the standards of 2022 edition from American Clinical Laboratory Standards Institute (CLSI). Statistical analysis was performed by WHONET 5.6 software. Data were analyzed by trend test (Cochran-armitage) and Chi-square test with SPSS. Results A total of 176 441 strains of P. aeruginosa were surveilled by Hunan Provincial Antimicrobial Resistance Surveillance System from 2012 to 2021. 99.4% of the strains were isolated from hospitalized patients, and about 70% of the strains were isolated from respiratory specimens. 8.4% of P. aeruginosa were from children (0-17 years old), 91.6% were from adults. Antimicrobial susceptibility testing results showed that P. aeruginosa was most sensitive to polymyxin B over 10 years, with a resis-tance rate of less than 6%. Resistance rates to piperacillin, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, imipenem, amikacin, gentamicin, tobramycin, ciprofloxacin, levofloxacin, and polymyxin B all showed downward trends. A total of 29 920 carbapenem-resistant P. aeruginosa (CRPA) strains were detected. The average isolation rate of CRPA in this province was 18.0% over 10 years. CRPA detection rate from adult was 18.5%, higher than that from children (12.3%), and both showing downward trends. Conclusion The resistance rate of clinically isolated P. aeruginosa in Hunan Province to most commonly used antimicrobial agents is decreasing.

    Reference
    Related
Get Citation

刘健龙,宋春荣,付敏,等.湖南省细菌耐药监测网2012—2021年铜绿假单胞菌耐药性监测报告[J].中国感染控制杂志英文版,2023,(12):1452-1459. DOI:10.12138/j. issn.1671-9638.20233827.
Jian-long LIU, Chun-rong SONG, Min FU, et al. Antimicrobial resistance of Pseudomonas aeruginosa: surveillance report from Hunan Provincial Antimicrobial Resistance Surveillance System, 2012-2021[J]. Chin J Infect Control, 2023,(12):1452-1459. DOI:10.12138/j. issn.1671-9638.20233827.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:October 10,2023
  • Revised:
  • Adopted:
  • Online: April 28,2024
  • Published: